A significant proportion of patients with COVID-19 develop acute respiratory distress
syndrome (ARDS) with high risk of death. The efficacy of veno-venous extracorporeal …

No study has compared patients with COVID-19-related refractory ARDS requiring veno-
venous extracorporeal membrane oxygenation (VV ECMO) to a relevant and homogenous …

OBJECTIVES: Determine the factors associated with mortality in venovenous extracorporeal
membrane oxygenation (VV ECMO) patients with COVID-19 infection and provide an …

Introduction Veno-venous extracorporeal membrane oxygenation (VV ECMO) has become a
support modality for patients with acute respiratory failure refractory to standard therapies …

Background Veno‐venous extracorporeal membrane oxygenation (V‐V ECMO) support is
increasingly used in the management of COVID‐19‐related acute respiratory distress …

Acute respiratory distress syndrome (ARDS) in COVID-19 patients is associated with poor
clinical outcomes and high mortality rates, despite the use of mechanical ventilation. Veno …

Survival of coronavirus disease 2019 (COVID-19) patients with severe respiratory failure
treated with venovenous extracorporeal membrane oxygenation (VV ECMO) ranges around …

Background The use of veno-venous extracorporeal membrane oxygenation (VV-ECMO) in
severe hypoxaemic respiratory failure from coronavirus disease 2019 (COVID-19) has been …

The role of veno-venous extracorporeal membrane oxygenation therapy (VV ECMO) in
severe COVID-19 acute respiratory distress syndrome (ARDS) is still under debate and …

Background Patients with COVID-19 and severe acute respiratory failure may require veno-
venous extracorporeal membrane oxygenation (VV ECMO). Yet, this procedure is resource …